

EARLY-PHASE ONCOLOGY DEVELOPMENT WITH TRANSLATIONAL AND BIOANALYTICAL EXPERTISE

QPS is a leading full-service global CRO with an experienced and dedicated global team providing comprehensive services from preclinical studies to bioanalysis and all phases of clinical trials. QPS supports oncology sponsors from first-in-human through proof-of-concept by combining early-phase clinical expertise, bioanalytical support, and biomarker and PK/PD-driven development.

WHY CHOOSE QPS FOR ONCOLOGY STUDIES?

1. Oncology Drug Development is Complex

- ▶ First-in-human and dose escalation requires careful safety assessment and dose selection
- ▶ Biomarker strategies are critical for patient selection and demonstrating mechanism of action
- ▶ PK/PD and translational endpoints are essential for understanding exposure/response relationships and guiding decisions
- ▶ Recruitment of targeted patient populations can impact study timelines

2. Early-Phase Oncology Studies

- ▶ First-in-human (FIH)
- ▶ Dose escalation and dose expansion
- ▶ PK/PD and safety evaluation
- ▶ Patient-based studies and healthy volunteer studies

3. Global Bioanalytical Laboratories

- ▶ PK/PD analysis
- ▶ Biomarker integration

4. Flexible Access to Oncology Expertise

- ▶ A global network of investigators and key opinion leaders
- ▶ Clinical and scientific teams supported by experienced oncology specialists

5. Global Study Execution

- ▶ Flexible model tailored to study and sponsor needs
- ▶ Clinical operations across North America, Europe, and Asia
- ▶ Coordinated execution from early-phase through later-stage studies
- ▶ Experience supporting multinational oncology studies across regions

6. Oncology Experience

- ▶ Studies across solid tumours and other malignancies
- ▶ Small molecules, biologics, and ATMPs
- ▶ Support for early- and late-phase clinical trials

CLINICAL RESEARCH OPERATIONS

- | | | |
|---------------------------------|-----------------------------------|--------------------------------|
| ▶ Project Management | ▶ Data Management & Biostatistics | ▶ Regulatory & Medical Affairs |
| ▶ Clinical Program Management | ▶ Medical Writing | ▶ Safety & Pharmacovigilance |
| ▶ Clinical & Medical Monitoring | ▶ Quality Assurance | ▶ Site Selection & Monitoring |

ONCOLOGY KEY OPINION LEADER (KOL) NETWORK

▶ Europe

- Dr. Mindaugas Jievaltas, Urologist | University Hospital Kaunas/Clinic of Modern Oncology | Lithuania
- Dr. Vincas Urbonas, Medical Oncologist | Early Phase Clinical Trials Lead | National Cancer Institute | Lithuania
- Christina Junvik, Masters Biopharmaceutical Sciences | Early Drug Development in Oncology | Sweden


▶ USA

- Dr. Bruno Fang, Oncologist | Director of Clinical Research at Astera Cancer Care | New Jersey
- Dr. Gordon Brown, Uro-Oncologist | Summit Health/New Jersey Urology | New Jersey
- Dr. Raoul Concepcion, Uro-Oncologist | US Urology Chief Medical Officer | Tennessee

▶ Taiwan

- Dr. Yen-Hwa Chang, Uro-Oncologist | Taipei Veterans General Hospital | Taiwan
- Dr. Peng-Hui Wang Director, Obstetrics and Gynecology | Taipei Veterans General Hospital | Taiwan
- Dr. See-Tong Pang, Uro-Oncologist | Chang Gung Memorial Hospital (CGMH) | Taiwan

ONCOLOGY CLINICAL TRIALS SITE NETWORK LOCATIONS



Pharmacology



Toxicology



DMPK



Bioanalysis



Translational
Medicine



Phase I Clinics



Regulatory &
Medical



Central Lab
Services

Discover how QPS can accelerate your clinical research.

Email: infobd@qps.com | Phone: 512-350-2827 | Website: www.qps.com